Research

Amivantamab is an epidermal growth factor receptor (EGFR)-MET bispecific antibody with immune cell-directing activity.

Constantina Boikos, Lauren Fischer, Dan O’Brien, Joe Vasey, Gregg C Sylvester, James A Mansi
This study estimated the relative vaccine effectiveness (rVE) of ccIIV4 versus egg-derived inactivated quadrivalent influenza vaccine (eIIV4) in preventing influenza-related medical encounters in the 2018–2019 US season.

Aaron Baum

Xinming Du
The study examined how intrahousehold transmission of COVID-19 is impacted by gender inequities.

Katie Martin, Daniel Kurowski, Phillip Given, Kevin Kennedy, Elianna Clayton
HCCI’s work shows submitted claims for most preventive services we examined, such as mammography and childhood immunizations exhibited significant declines in 2020 compared to 2019, particularly mid-March through mid-April. Even by June 2020 utilization of many preventive services appeared to be running below 2019 levels

Daniel Kurowski, Katie Martin, Anna Milewski, Angela Pupino, Niall Brennan
For the sample population, the disparity in infections among Black and Hispanic communities is significantly higher than most current assumptions. Additionally, patients presenting in an office or clinic setting who test positive are more likely to be younger and less likely to be older than 65.

Dustin D. French, Andrew Chin, and Pooja Kathail

Utilizing consumer data, mortality data, and medical claims data from the COVID-19 Research Database, French, Chin, and Kathail helped quantify the disproportionate impact that COVID-19 has across different racial and socioeconomic groups. For instance, the bottom quartile of income distribution (under $49,000 in annual income) have 30 percent of COVID cases and 46 percent of COVID deaths. Meanwhile, the top quartile (over $144,000 in annual income) had only 11 percent of COVID deaths.

Mohammad Akbarpour, Cody Cook, Aude Marzuoli, Simon Mongey, Abhishek Nagaraj, Matteo Saccarolak, Pietro Tebaldi, Shoshana Vasserman, and Hanbin Yang
Researchers from Harvard, Stanford, the University of Chicago, and Berkeley created a methodology for deciding which locations in a city to re-open and which to keep closed. The authors utilized a wide variety of data sources to build their models, including electronic medical records from the COVID-19 Research Database. After its completion, the model was then tested across three different cities: Chicago, Sacramento, and New York.